![]() All alprazolam treatments resulted in significantly greater sedation than placebo on days 1 and 4. Acute and chronic tolerance to the sedative and psychomotor effects was observed with all active drug treatments. Accumulation of these metabolites and alprazolam was dependent on alprazolam half-life (11.6 h). Plasma concentrations of the 4- and α-hydroxy metabolites of alprazolam were less than 10% of unchanged alprazolam levels on both days. On days 1 and 4, the kinetics, sedative and psychomotor effects were evaluated. Active drug treatments consisted of 4-day regimens of 4 mg alprazolam PO daily as 2 mg bid., 1 mg qid, and 0.25 mg each hour. The relationships between alprazolam and metabolite concentrations and CNS effects were determined in a double-blind placebo controlled four-way crossover trial in 16 normal male volunteers. ![]()
0 Comments
Leave a Reply. |